Rapport Therapeutics (RAPP)
Develops RAP-targeted neuromedicines, with RAP-219 advancing across seizure and bipolar mania programs.
Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP
Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 32,212 shares of the company's stock, valued at approximately $1,342,000. Deutsche Bank AG owned about
Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP
Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 223,822 shares of the company's stock, valued at approximately $9,327,000. Algert Global LLC owned about 0.47% of Rapport Therapeutics
Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Time to Buy?
Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.34 and last traded at $49.33, with a volume of 365422 shares changing hands. The stock had previously closed at $48.24. Analyst Upgrades and Downgrades A number of research
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline. "We remain focused on disciplined execution as we deliver against several important catalysts this year," said Abraham N.
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from 159,914 to 149,914 shares.
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,” said Abraham N.
Modalités de mise à disposition du rapport financier annuel 2025
MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son Rapport Financier Annuel 2025.Le Rapport Financier Annuel peut être consulté sur le site internet de la société à l'adresse www.advini.com/finance - rubrique Informations Réglementées. A PROPOS D'ADVINI Fondé en 1872, AdVini est un groupe viticole international, porté par une âme familiale, un actionnariat visionnaire et humaniste et un esprit d'entreprendre.
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), société pharmaceutique spécialisée en phase avancée de développement et d'enregistrement de ZEPIZURE®, sa solution d'urgence pour la gestion des crises d'épilepsie, annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son rapport financier annuel 2025. Le rapport financier annuel 2025 peut être consulté sur le site internet de la société.
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains.
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures (FOS) in a late-breaker podium presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago. In the Phase 2a trial, patients received RAP-219 for 8 weeks and then entered an 8-week follow-up period after treatment ended to evaluate the effect of RAP-219 on long episodes (LEs) – an objective biomarker of epileptiform activity with >90% median concordance with electrographic seizures in this trial – and clinical seizures.
Communiqué de mise à disposition du rapport financier annuel 2025
A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mise à disposition du Rapport financier annuel 2025 de Crédit Mutuel Home Loan SFH Crédit Mutuel Home Loan SFH informe que ce document est à la disposition du public sur le site de l'émetteur, à l'adresse suivante : https://www.creditmutuel-homeloansfh.eu/en/covered-bonds/documentation/investor-documents.html Ce document est également disponible sur le site de l'AMF. Contact Relations Investisseurs Banque Fédérative du Crédit Mutuel Sandrine Cao Dac Viola : bfcm-web@creditmutuel.fr Attachment Crédit Mutuel Home Loan SFH - Communiqué de mise à disposition du Rapport financier annuel 2025
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Target Price at $51.40
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware
LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. The collaboration combines Neuphonic's ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, u.
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago.
CRCAM Toulouse 31 - Rapport financier annuel 2025
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript